Latest News
Web Date: January 9, 2017

Deal deluge hits at start of JPMorgan Healthcare meeting

Takeda, Ipsen, and Allergan are among those adding to their portfolios
Department: Business
Keywords: mergers & acquisitions, biotech, Allergan, cancer, JPMorgan

Rain and wind might have caused travel turmoil for the hordes descending upon San Francisco for the annual J.P. Morgan Healthcare Conference this week, but the weather did not slow down the pharmaceutical deal-making. The first official day of the event brought a cluster of pacts, kicking off a year expected to be heavy with biotech acquisitions.

The biggest deal is Takeda Pharmaceuticals’ $5.2 billion purchase of cancer drug developer Ariad Pharmaceuticals. Takeda gains the . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society